Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

Unsurprisingly, Akero owes this incredible one-day gain to data from a midstage clinical trial. Akero Therapeutics is ...

As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

It does not provide Zepbound for people whose doctors have prescribed it off-label. Off-label means that a doctor prescribes a medication for a reason or at a dose the FDA has not approved.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Zepbound is a GLP-1 agonist containing tirzepatide ... they aren’t approved for off-label use. Off-label use and shortages can lead to complications, including insurance issues.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...